AstraZeneca: CHMP recommends Lynparza

(CercleFinance.com) - The Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Lynparza for the treatment of patients with BRCA-mutated metastatic pancreatic cancer.


The biopharmaceutical group has said that the European Medicines Agency (EMA) release was based on Phase III clinical results showing a longer median progression-free survival in the Lynparza group of around 7.4 months compared to 3.8 months in the placebo group.

Lynparza is being developed and marketed in collaboration with the US giant Merck.

In another notable development, Brilinta - which is also owned by AstraZeneca - has been approved by the US FDA in reducing the risk of heart attacks and strokes in patients with coronary heart disease, the most common heart condition today.


Copyright (c) 2020 CercleFinance.com. All rights reserved.